Clinical Trial Update: A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating GDC-0980 in patients with refractory solid tumors or Non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• GDC-0980

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Hodgkin's Lymphoma, Solid Cancers | Phase 1 | Status: COMPLETED